10-K: Stimcell Energetics Reports Deepening Losses, R&D Restart

Stimcell Energetics Inc. reported a significant increase in net loss for fiscal year 2025, alongside a restart of eBalance device redesign and ongoing reliance on related-party financing.

Summary

• Net loss for fiscal year 2025 increased by 297.4% to $566,293, compared to $142,486 in fiscal year 2024.
• Operating expenses rose by 94.6% to $522,106 in fiscal year 2025, up from $268,352 in fiscal year 2024.
• Research and development costs increased significantly to $64,009 in fiscal year 2025, from a recapture of $22,539 in fiscal year 2024, driven by a new partnership with ADM Tronics Unlimited, Inc.
• Management fees increased by 140% to $90,000 in fiscal year 2025, from $37,500 in fiscal year 2024.
• General and administrative expenses increased by 83.5% to $213,452 in fiscal year 2025, primarily due to a $130,065 increase in corporate communications.
• The company generated no revenue in either fiscal year 2025 or 2024.
• Working capital deficit widened by 50.8% to $1,246,286 as of May 31, 2025, from $826,455 as of May 31, 2024.
• Cash balance decreased to $14,581 as of May 31, 2025, from $43,415 as of May 31, 2024.
• The company funded operations in fiscal year 2025 with $112,858 borrowed from related parties.
• A 1-for-15 reverse stock split and name change from Cell MedX Corp. to Stimcell Energetics Inc. became effective November 1, 2024.
• Health Canada Class II Medical Device System Certifications for eBalance Home and Pro Systems were suspended on June 5, 2023, due to financial difficulties, and the FDA 510(k) application was withdrawn.
• The company established a new partnership in February 2025 to redesign the eBalance Home device into an eBalance Wellness consumer unit, aiming for market readiness in early 2026.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by increasing losses, zero revenue, widening working capital deficit, and a going concern warning. While there's a new R&D partnership, it's a pivot to a less regulated 'wellness' product, and the company's ability to fund operations and future growth remains highly uncertain, relying heavily on related-party financing.

Positives

• Established a new partnership with ADM Tronics Unlimited, Inc. in February 2025 to redesign the eBalance Home device into a compact, affordable consumer unit (eBalance Wellness).
• The new eBalance Wellness device designation will negate the process of seeking FDA medical device approval, potentially speeding up market entry and lowering costs.
• Past clinical observational trials (Fiscal 2018) on eBalance technology showed positive results, including a 12.3% decline in average fasting blood glucose, a 48% decline in plasma insulin, a 0.16% reduction in HbA1c, and improvements in blood pressure (systolic down 9.6%, diastolic down 10.4%).
• The company successfully registered the EBALANCE trademark in Canada, the European Union, the U.K., and the United States.

Negatives

• Net loss significantly increased by 297.4% to $566,293 in fiscal year 2025.
• Operating expenses increased by 94.6% to $522,106 in fiscal year 2025.
• The company generated no revenue in fiscal years 2025 or 2024.
• Working capital deficit worsened by 50.8% to $1,246,286.
• Cash balance declined to $14,581, indicating severe liquidity issues.
• Health Canada Class II Medical Device System Certifications for eBalance Home and Pro Systems were suspended on June 5, 2023, due to inadequate financing, halting revenue-generating activities.
• The FDA 510(k) clearance application was withdrawn due to the company's financial situation.
• Further research and development of eBalance Technology, including new clinical trials, were suspended due to lack of funding.
• The company has an accumulated deficit of $10,861,556 since inception.
• A $30,000 loan from CEO David Jeffs was in default as of May 31, 2025.
• Internal controls over financial reporting were deemed not effective due to lack of segregation of duties.

Risks

• Operates in a highly competitive market against large, well-established medical device and pharmaceutical companies with significant resources.
• Subject to numerous governmental regulations (FDA, Health Canada), which can increase costs and delay approvals; failure to comply or obtain approvals could severely impact the business.
• Inability to protect and enforce intellectual property rights, as eBalance Technology is not patented, could adversely affect financial results and allow competitors to compete more easily.
• Research and development efforts may not result in commercially successful products, leading to substantial expenditures without assurance of success.
• New products and technological advances by competitors could render the company's products obsolete.
• Significant safety concerns could arise for products, which could have a material adverse effect on revenues and financial condition.
• Inability to attract and maintain key personnel may cause the company's business to fail.
• Lack of operating history and minimal revenues, with no guarantee of future profitability, poses a risk of investors losing their entire investment.
• The company needs to acquire additional financing, or its business will fail, and there is no assurance that attempts to raise capital will be successful.
• Future offerings of shares or conversion of debt into shares will result in dilution to current shareholders.
• A limited market for common stock and penny stock rules may restrict shareholders' ability to resell shares and affect market price and liquidity.
• The company does not anticipate paying cash dividends on its common stock in the foreseeable future.
• The company's ability to continue as a going concern is in substantial doubt, dependent on continued financial support and obtaining necessary financing.

Future Outlook

The company plans to continue supporting its operations and the redesign of the eBalance microcurrent device through equity or debt financing. The redesigned eBalance Wellness unit is expected to be completed in Fall 2025 and ready for market in early 2026. However, the company cannot provide assurance that attempts to raise additional capital will be successful, and new clinical trials are currently suspended due to lack of funding.

Management Comments

• Management is planning to support its operations as well as redesign of the eBalance microcurrent device through equity or debt financing.
• The Company is unable to provide any assurance that its attempts to raise additional capital will be successful.

Industry Context

Stimcell Energetics operates in the highly competitive biotech and medical device industry, specifically targeting diabetes management and pain relief with its microcurrent therapy. While the market for diabetes care is substantial (537 million adults globally in 2021, projected to rise to 783 million by 2045), the company's microcurrent therapy is not yet widely accepted in traditional medicine. This places it in a niche with less defined direct competition but significant indirect competition from established pharmaceutical and medical device companies offering traditional treatments. The strategic pivot to an 'eBalance Wellness' device aims to bypass stringent FDA medical device approvals, aligning with a broader trend of consumer-focused health technology, but also potentially limiting medical claims and reimbursement opportunities.

Comparison to Industry Standards

• The company's eBalance technology, based on microcurrent therapy, is not widely accepted in traditional medicine, unlike products from major pharmaceutical and medical device companies such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc. (a division of Johnson & Johnson), MediSense Inc., and TheraSense Inc.
• Direct competitors in electrical/microcurrent therapies include BodiHealth Systems, focusing on the pain relief market in the US, and Electromedical Products International, Inc., which developed Alpha-Stim PPM for pain relief.
• The company's clinical study showed a 0.16% reduction in HbA1c, which is less than the 1% reduction shown in studies like the UK Prospective Diabetes Study (UKPDS) to significantly lower the risk of microvascular complications by 25%.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceedings, and none of its properties or assets are the subject of any pending legal proceedings.

Related Party Transactions

• The company owed David Jeffs (CEO, Director) $144,237 for unpaid management fees and reimbursable expenses as of May 31, 2025.
• The company owed David Jeffs $47,615 under loan agreements (10% annual interest, due on demand), with a $30,000 loan in default as of May 31, 2025.
• The company owed $32,229 to a company of which David Jeffs is a director (6% annual interest, due on demand).
• The company owed Yanika Silina (CFO) $8,778 for unpaid consulting fees and reimbursable expenses as of May 31, 2025.
• The company incurred $30,000 in consulting fees to Yanika Silina in fiscal year 2025.
• The company owed Da Costa Management Corp. (controlled by director John Da Costa) $295,521 for unpaid consulting and accounting fees and reimbursable expenses as of May 31, 2025.
• The company incurred $107,488 in consulting and accounting fees to Da Costa Management Corp. in fiscal year 2025.
• The company owed Amir Vahabzadeh (Director) $185,297 under loan agreements (10% annual interest, due on demand), with a $30,000 note in default as of May 31, 2025.
• Mr. Vahabzadeh advanced $60,000 to the company in November 2024 and March 2025.
• The company owed Richard Jeffs (significant shareholder, father of CEO) $94,253 under notes payable (6% and 10% annual interest, due on demand) as of May 31, 2025.
• Richard Jeffs provided a new line of credit for US$200,000 on June 20, 2025, which was amended on July 21, 2025, to CAD$250,000.
• The company owed Sam Ahdoot (significant shareholder) $72,756 under unsecured notes payable (10% annual interest, due on demand) as of May 31, 2025.
• The company borrowed $25,747 from Mrs. Susan Jeffs (spouse of Richard Jeffs) under a non-secured credit line (10% per annum, due on demand) in fiscal year 2025.
• Debt settlement agreements in December 2023 converted $1,622,693 of debt, primarily from related parties, into 15,454,221 shares of common stock, resulting in a change of control.

Stakeholder Impact

• Shareholders face significant dilution from past debt conversions and expected future capital raises, with a high risk of total loss due to going concern issues and penny stock status, and limited market liquidity.
• Executive officers and consultants face risks of non-payment or delayed payment due to financial difficulties, as their compensation is primarily through consulting fees and some shares.
• Creditors, particularly related parties, are exposed to high risk due to significant amounts owed, some of which are in default, and the company's continued reliance on related-party financing.
• Customers may see a new 'eBalance Wellness' product in early 2026, but previous medical device products (eBalance Home/Pro) are no longer certified or approved for sale.
• Regulatory bodies have noted past non-compliance with Health Canada certifications and withdrawal of FDA applications, highlighting ongoing regulatory risks and operational challenges.

Next Steps

• Complete the redesign of the eBalance Wellness microcurrent device, expected in Fall 2025.
• Prepare the eBalance Wellness device for market readiness in early 2026.
• Secure additional equity or debt financing to support operations and further research and development.
• Address the 'substantial doubt' about the company's ability to continue as a going concern.
• Potentially conduct a longer, double-blind, placebo-controlled study to further assess HbA1c reduction and other clinical benefits of eBalance therapy, if funding becomes available.
• Explore developing specialized software/treatment options for other ailments such as gout, hypertension, heart disease, neurological disorders, and depression, if financially stable.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by zero revenue, a substantial increase in net loss, a widening working capital deficit, and a 'going concern' warning from its auditors. Its core medical device products lost regulatory certifications and FDA applications were withdrawn due to financial issues. While a pivot to a 'wellness' product is underway, it's unproven, and the company's survival is entirely dependent on securing highly uncertain future financing, likely leading to further significant shareholder dilution. The extensive reliance on related-party debt, some of which is in default, further underscores the precarious financial position. This presents an extremely high-risk investment with a high probability of further capital erosion.

Keywords

Biotech, Microcurrent therapy, eBalance Technology, Diabetes management, Pain relief, Medical device, Wellness products, SEC filing, 10-K, Stimcell Energetics, Cell MedX, Financial reporting, Going concern, Capital raise, Regulatory approval, FDA, Health Canada, Research and development, Related party transactions, Stock split, Corporate governance